Cargando…

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50–75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicoś, Marcin, Krawczyk, Paweł, Crosetto, Nicola, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746867/
https://www.ncbi.nlm.nih.gov/pubmed/33344229
http://dx.doi.org/10.3389/fonc.2020.569202
_version_ 1783624882136809472
author Nicoś, Marcin
Krawczyk, Paweł
Crosetto, Nicola
Milanowski, Janusz
author_facet Nicoś, Marcin
Krawczyk, Paweł
Crosetto, Nicola
Milanowski, Janusz
author_sort Nicoś, Marcin
collection PubMed
description Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50–75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic level is considered as a major cause of anticancer therapy failure, including resistance to ICIs. Recent observations suggest that spatial heterogeneity in the composition and spatial organization of the tumor microenvironment plays a major role in the response of M-NSCLC patients to ICIs. In this mini review, we first present a brief overview of the use of ICIs in M-NSCLC. We then discuss the role of genetic and non-genetic ITH on the efficacy of ICIs in patients with M-NSCLC.
format Online
Article
Text
id pubmed-7746867
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77468672020-12-19 The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors Nicoś, Marcin Krawczyk, Paweł Crosetto, Nicola Milanowski, Janusz Front Oncol Oncology Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50–75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic level is considered as a major cause of anticancer therapy failure, including resistance to ICIs. Recent observations suggest that spatial heterogeneity in the composition and spatial organization of the tumor microenvironment plays a major role in the response of M-NSCLC patients to ICIs. In this mini review, we first present a brief overview of the use of ICIs in M-NSCLC. We then discuss the role of genetic and non-genetic ITH on the efficacy of ICIs in patients with M-NSCLC. Frontiers Media S.A. 2020-12-04 /pmc/articles/PMC7746867/ /pubmed/33344229 http://dx.doi.org/10.3389/fonc.2020.569202 Text en Copyright © 2020 Nicoś, Krawczyk, Crosetto and Milanowski http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Nicoś, Marcin
Krawczyk, Paweł
Crosetto, Nicola
Milanowski, Janusz
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title_full The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title_fullStr The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title_full_unstemmed The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title_short The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
title_sort role of intratumor heterogeneity in the response of metastatic non-small cell lung cancer to immune checkpoint inhibitors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746867/
https://www.ncbi.nlm.nih.gov/pubmed/33344229
http://dx.doi.org/10.3389/fonc.2020.569202
work_keys_str_mv AT nicosmarcin theroleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT krawczykpaweł theroleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT crosettonicola theroleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT milanowskijanusz theroleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT nicosmarcin roleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT krawczykpaweł roleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT crosettonicola roleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors
AT milanowskijanusz roleofintratumorheterogeneityintheresponseofmetastaticnonsmallcelllungcancertoimmunecheckpointinhibitors